Overview

• THC: 800mg/g
• CBG: 40mg/g
• Plant Species: Sativa
• Cultivar: Mimosa
• Aromas & Flavors: Sweet, Citrus
• Spectrum: Full Spectrum
• Schedule: 8

Appearance

The product development team at Superbly Green has clearly put a lot of effort into the design of the Zingy Cartridge. The unit itself stands out with the strain name etched onto the glass and bold “ZINGY” branding displayed. The oil is a beautiful golden color with a refined clarity that instantly suggests quality. While the hardware itself is standard and in line with other cartridges on the market, the design details give it a premium feel.

Flavour

In terms of flavour into citrus, with hints of lime, lemon, and grapefruit coming through. It tastes fresh and natural, which is likely due to a combination of the LSO (Living Organic Soil) flower and meticulous extraction methods. So far, I’m halfway through the cartridge, I have found the flavor has remained consistent – Unlike some other distillate carts that can turn murky and develop a metallic taste over time, yum.

Potency

The onset of effects takes about 15-30 minutes, depending on how much you use, and the high is more on the energizing and balanced side rather than cerebral or heavy. It feels “light” and uplifting, making it a good option for daytime use or when you need to stay functional and focused. While the effects don’t pack an intense punch, they are steady and pleasant, which aligns well with the strain’s Sativa-leaning profile.

Experience

As with many distillate cartridges, the vapor can be a bit harsh if you’re not careful with the temperature settings. I found using a lower-temp 510 battery and taking shorter draws (3-5 seconds) made for a smoother experience. The vapor production is light and wispy—not the thick clouds you’d expect from nicotine vapes, but typical for distillate carts. I did experience some clogging, this is totally normal for cartridges to do so. If I had a pre-heat function on my battery it would be a completely different story. In regard to 510 batteries, I try to avoid the auto-inhale variants for this reason, most of them don’t have the pre-heat function.

Value

At $129, the Zingy cartridge is priced fairly for what it offers. Considering the effort Superbly Green puts into cultivating high-quality LSO (Living Soil Organic) flower before turning it into distillate, I can appreciate the process. While there are cheaper options on the market, they often sacrifice longevity and flavour, becoming murky and unpleasant over time. That said, the hardware issues are a downside, and I’d love to see Superbly experiment with a live resin option in the future.

Brand Reputation

Superbly Green is an Australian cannabis brand based in Northern Rivers, NSW, known for their small-batch, organically grown flower. They emphasize sustainable and clean growing practices, making them a standout in the local market. Their attention to detail and commitment to quality is evident in their products, including the Zingy cartridge.

Final Thoughts

Bunny approved ✅

The Zingy cartridge by Superbly Green delivers a well-rounded experience with vibrant citrus flavors and balanced effects, making it an excellent choice for daytime use. The distillate stands out for its quality and consistency.

At $129, it offers solid value for an Australian-made product that emphasizes craftsmanship and quality. I think with a few tweaks to the hardware and the addition of a live resin variant, this product could easily staple.

Rating: 🌟🌟🌟🌟 (4/5)

Key Takeaways

• The FDA has approved a study to investigate cannabis as a treatment for PTSD.
• The study aims to determine how cannabis can manage symptoms like anxiety, flashbacks, and hyperarousal.
• Cannabis compounds such as THC and CBD interact with the body’s endocannabinoid system to regulate mood and stress.
• If successful, this research could lead to improved PTSD treatments and influence cannabis policy reform.
• The study highlights the importance of reducing the stigma around medical cannabis use.

The U.S. Food and Drug Administration (FDA) has approved a landmark study to explore cannabis as a treatment for post-traumatic stress disorder (PTSD). This decision is a significant step in advancing medical cannabis research, offering hope to those who struggle with managing PTSD symptoms through traditional treatments.

PTSD impacts millions worldwide, particularly veterans, trauma survivors, and individuals exposed to extreme stress. While therapy and prescription medications are common treatments, they don’t always provide adequate relief. Cannabis, which contains compounds like THC and CBD, is being explored for its potential to regulate mood, reduce anxiety, and improve sleep. The FDA’s approval signals growing interest in cannabis as a legitimate treatment option for mental health conditions.

The study will focus on understanding how cannabis can help manage PTSD symptoms such as chronic anxiety, flashbacks, nightmares, and hyperarousal. By evaluating different cannabis formulations and dosages, researchers aim to determine which combinations work best to alleviate these symptoms. This research could serve as a foundation for more personalized, effective PTSD treatment plans.

Cannabinoids interact with the body’s endocannabinoid system, which regulates mood, stress, and fear responses. Preliminary findings suggest cannabis may offer benefits for PTSD patients, including reduced anxiety, improved sleep, and lowered stress responses. However, more comprehensive studies like this FDA-approved trial are essential to confirm these effects and establish safety guidelines.

The implications of this study could extend beyond PTSD. If cannabis is shown to be effective, it may lead to policy changes at the federal and state levels, broadening access to medical cannabis. The FDA’s support also helps reduce the stigma associated with cannabis use, encouraging patients and healthcare providers to discuss it as part of a treatment strategy.

The approval of this study represents a significant milestone in medical cannabis research, potentially paving the way for better treatment options for PTSD patients and advancing the broader conversation about cannabis in healthcare.

By supporting this research, the FDA is advancing the potential of cannabis to become a key part of modern mental health treatment. For individuals struggling with PTSD, this study may provide new hope and a pathway to better care.

The University of Illinois System has taken a huge step forward in the cannabis industry with the launch of a state-funded Cannabis Research Institute. This multi-million-dollar initiative marks a significant leap toward advancing cannabis research, focusing on areas like medical innovation, economic growth, and public health.

Why This Initiative Matters

The cannabis industry is booming, but there’s still much to learn about its potential and challenges. Illinois’ Cannabis Research Institute aims to bridge the gaps in knowledge, addressing key issues such as safety, sustainability, and policy development.

The initiative is set to have a major impact in several areas:

• Advancing medical research to explore cannabis’ therapeutic potential.
• Driving economic growth by fostering industry innovation and job creation.
• Informing public policy with evidence-based insights.

Key Focus Areas of the Cannabis Research Institute

Medical Advancements

One of the institute’s priorities is to understand how cannabis can be used to treat a wide range of medical conditions. Research will explore its effectiveness for chronic pain, anxiety, epilepsy, and other health challenges, with an emphasis on developing evidence-based applications.

Sustainability

Large-scale cannabis cultivation presents environmental challenges. The institute will study sustainable farming practices, energy-efficient cultivation methods, and strategies to reduce water usage. These efforts aim to ensure that the industry grows responsibly.

Safety and Accessibility

Ensuring consumer safety is critical. The institute will focus on product quality, safe dosages, and potential side effects. It will also explore ways to make cannabis more accessible to those who need it most, including patients and marginalized communities.

Social Equity

Acknowledging the disproportionate impact of past cannabis regulations on certain communities, the initiative includes a strong focus on social equity. It seeks to ensure that the benefits of research and industry growth are distributed fairly.

Illinois as a Leader in Cannabis Innovation

Illinois has already made waves in the cannabis industry, with over $1 billion in sales and reinvestment in community programs since legalizing recreational use. The Cannabis Research Institute solidifies the state’s reputation as a pioneer by combining economic progress with a commitment to public health and sustainability.

What This Means for the Future

The launch of the Cannabis Research Institute is more than a state milestone—it’s a model for global cannabis research. By fostering collaboration between scientists, industry leaders, and policymakers, Illinois is paving the way for innovation that could shape the industry worldwide.

From developing new medical treatments to advancing sustainability, the work conducted here has the potential to redefine the cannabis landscape, benefitting both consumers and businesses alike.

Conclusion

Illinois’ bold investment in cannabis research is a visionary step forward. By addressing critical knowledge gaps and fostering meaningful innovation, the Cannabis Research Institute is poised to unlock new opportunities and set a global standard for how research can drive industry progress.

Key Takeaways:

• J.P. Graziano, a renowned Chicago-based Italian grocery, has partnered with cannabis company nuEra to create GiardinuEra, a THC-infused version of their classic giardiniera.
• Each 4-ounce jar contains 25mg of THC and is priced at $14, available at nuEra locations and select dispensaries in Illinois.
• This collaboration reflects a growing trend of integrating cannabis into traditional culinary products, offering consumers unique and localized edible experiences.

In a fusion of culinary tradition and modern cannabis culture, Chicago’s esteemed Italian grocery, J.P. Graziano, has teamed up with local cannabis company nuEra to launch GiardinuEra—a THC-infused rendition of their iconic giardiniera. This innovative product combines the classic spicy pickled condiment with cannabis, offering a novel experience for consumers.

A Culinary Tradition Meets Cannabis Innovation

Giardiniera, a staple in Chicago’s culinary scene, is traditionally used to enhance dishes like Italian beef sandwiches, pizzas, and burgers. J.P. Graziano, a family-owned business operating since 1937, is renowned for its authentic Italian offerings, with giardiniera being a flagship product. The collaboration with nuEra emerged when a long-time customer, now working with the cannabis company, proposed the idea, aligning with J.P. Graziano’s interest in exploring the cannabis market.

Product Details and Availability

GiardinuEra is crafted using J.P. Graziano’s hot giardiniera recipe, infused with 25mg of THC per 4-ounce jar. Priced at $14, this limited-edition product is available exclusively at nuEra dispensaries and select other locations across Illinois. Given the THC content, it is intended for consumers aged 21 and over.

The Growing Trend of Cannabis-Infused Culinary Products

This collaboration reflects a broader trend of incorporating cannabis into traditional food items, catering to consumers seeking unique edible experiences. By blending a beloved local condiment with cannabis, J.P. Graziano and nuEra offer a product that resonates with Chicago’s rich culinary heritage while embracing contemporary cannabis culture.

Conclusion

The introduction of GiardinuEra marks a significant milestone in the evolving landscape of cannabis-infused foods. For Chicagoans and visitors alike, it presents an opportunity to experience a cherished local delicacy with a modern twist, reflecting the dynamic interplay between tradition and innovation in the city’s food scene.

Key Takeaways:

• Cannabis is increasingly being explored as a treatment to alleviate symptoms associated with dementia, such as anxiety, agitation, and sleep disturbances.
• Preliminary studies and anecdotal evidence suggest potential benefits, but comprehensive clinical research is still needed to confirm efficacy and safety.
• Caregivers and healthcare providers are considering cannabis as an alternative when traditional medications prove ineffective or cause adverse side effects.
• The legal status of cannabis varies by region, impacting accessibility for patients and families seeking this form of treatment.

Dementia, encompassing conditions like Alzheimer’s disease, presents significant challenges for patients and caregivers due to symptoms such as agitation, anxiety, and disrupted sleep patterns. Traditional treatments often involve anti-psychotic medications, which may have limited effectiveness and undesirable side effects. In this context, cannabis has emerged as a potential alternative therapy, garnering attention for its possible role in managing dementia-related symptoms.

Potential Benefits of Cannabis for Dementia Symptoms

Some healthcare professionals have observed that cannabis may help alleviate certain behavioral and psychological symptoms of dementia. Dr. Jeffrey Hergenrather, a general practitioner specializing in cannabis consultations, notes that approximately 20% of his patients seek cannabis treatment for dementia-related issues. Patients and caregivers report improvements in anxiety levels, agitation, and sleep quality, contributing to an enhanced quality of life. (wsj.com)

Current Research and Evidence

While anecdotal reports are promising, scientific research on cannabis use in dementia care remains in its early stages. A recent study involving 75 Alzheimer’s patients indicated that administering 5 mg of synthetic THC twice daily significantly reduced agitation compared to a placebo. However, the study also reported increased drowsiness among some participants, highlighting the need for further investigation into optimal dosing and potential side effects. (hopkinsmedicine.org)

The Alzheimer’s Association emphasizes the necessity for more comprehensive research to understand the benefits and risks of cannabis use in dementia treatment. Currently, there is no conclusive evidence supporting cannabis as a treatment or prevention method for Alzheimer’s disease. (alz.org)

Considerations for Caregivers and Patients

For caregivers contemplating cannabis as a treatment option, several factors should be considered:

• Consult Healthcare Providers: Engage with medical professionals to discuss potential benefits and risks, considering the patient’s overall health and existing medications.
• Legal Status: Be aware of the legal status of cannabis in your region, as it varies and may affect accessibility.
• Monitor Effects: Carefully observe the patient’s response to cannabis, noting any improvements or adverse reactions, and adjust the treatment plan accordingly.

Conclusion

The exploration of cannabis in dementia care reflects a growing interest in alternative therapies to manage challenging symptoms. While preliminary findings and personal accounts suggest potential benefits, the current lack of extensive clinical research necessitates caution. Caregivers and patients should collaborate closely with healthcare providers to make informed decisions, balancing the promise of symptom relief with the need for safety and efficacy.

• Cannabis as a Substitute: Many people find cannabis helpful in reducing the use of more harmful substances, particularly alcohol, opioids, and methamphetamine.
• Demographic Differences: Young adults and the Māori population in New Zealand show significant substitution patterns, while adolescents exhibit mixed effects.
• Harm Reduction: Increased cannabis access might offer safer alternatives for individuals at risk of substance misuse, potentially decreasing alcohol and methamphetamine abuse.
• Cultural Shifts: Attitudes toward cannabis are changing, with more adults in the U.S. viewing it as less harmful and more beneficial than alcohol and opioids.

A new study from New Zealand has found that cannabis might serve as a substitute for more harmful substances, such as alcohol, opioids, and methamphetamine, reducing the consumption of these drugs for many users. Surveying 23,500 people, researchers revealed that cannabis use could play a significant role in harm reduction, especially among younger adults.

Key Findings

The study showed a considerable reduction in the use of certain drugs among cannabis users:

• Alcohol: 60% of respondents reported drinking less.
• Synthetic Cannabinoids: 60% reduced their use.
• Morphine: 44% used less.
• Methamphetamine: 40% lowered their intake.

For some, cannabis did not impact the usage of other drugs, such as LSD, MDMA, and cocaine. However, one-third of respondents who used both cannabis and tobacco reported smoking less.

Age and Demographic Impact

Younger adults (ages 21-35) were more likely to report that cannabis reduced their alcohol and methamphetamine use. Adolescents (ages 16-20) had mixed outcomes, with some reporting increased use of other substances. The Māori population in New Zealand, along with young men, noted significant reductions in alcohol and other drug use after starting cannabis, despite high baseline rates of hazardous drinking.

Variability Across Jurisdictions

The findings align with mixed results seen in other regions. For example:

• U.S. College Students: In areas where cannabis is legalized, some studies observed a decrease in binge drinking among students over 21, though the same effect wasn’t seen in younger students.
• Alcohol Sales Post-Legalization: In Canada, legalization correlated with decreased beer sales. In the U.S., monthly alcohol purchases dropped in some legalized states.

Potential Reasons for Substitution

Researchers suggest that similar neurological effects, social acceptability, and price comparisons between alcohol and cannabis may drive this substitution. Studies also indicate that some people use cannabis specifically to reduce alcohol consumption and avoid related negative outcomes.

Implications for Harm Reduction

The study highlights potential benefits of increased cannabis access:

1. Reducing Excessive Drinking: Among young adults with high rates of risky drinking, cannabis could offer a safer alternative.
2. Mitigating Methamphetamine Use: Cannabis might help individuals decrease methamphetamine consumption or support treatment for meth-related issues.

Some programs advocate for community-led harm reduction models that provide cannabis at low cost to people with substance use issues.

Observations in the U.S. and Canada

Public perception aligns with the study’s findings, as recent surveys show Americans increasingly view cannabis as less harmful and addictive than alcohol or opioids. Polls reveal that more Americans now smoke cannabis daily than consume alcohol daily.

This research contributes to a growing understanding of how cannabis legalization may affect other drug use, indicating potential benefits for harm reduction and public health.